Samsung Biologics Makes First Appearance at AACR, Launches Expansion of Full-Cycle CRDMO Business

Organoid and Bispecific Antibody Platforms Unveiled

Showcasing Technological Strength at a Preclinical-Focused Conference

Samsung Biologics has launched efforts to expand its Contract Research, Development, and Manufacturing Organization (CRDMO) business at a global cancer conference.

Samsung Biologics booth is being operated at the American Association for Cancer Research (AACR) held in San Diego, USA on the 20th. Samsung Biologics

On April 20, Samsung Biologics announced that it participated in the American Association for Cancer Research (AACR), where it introduced its CRDMO capabilities, which encompass CRO, CDO, and CMO services. This is the first time the company has taken part in the AACR.

The AACR is the largest conference in the field of cancer research, attracting approximately 22,000 attendees from about 140 countries worldwide. It is considered one of the "world's top three cancer conferences," alongside the American Society of Clinical Oncology (ASCO) and the European Society for Medical Oncology (ESMO). This year's event is being held from April 17 to 22 in San Diego, USA.

Samsung Biologics has set out a strategy to focus on securing customers in the early development stages, considering the AACR's emphasis on preclinical and early clinical research. The company aims to establish an "early lock-in" structure, starting collaboration from the CRO and CDO stages and continuing through to commercial production.

At the event, the company is conducting oral and poster presentations along with operating its booth. It is introducing the potential for new drug development using patient-derived models, centered around its organoid-based platform, "Samsung Organoid." According to the company, it has secured correlation with clinical outcomes by reflecting the genetic characteristics and drug responses of actual patients. In addition, data related to its bispecific antibody platform, "S-DUAL," will also be released.

Recently, Samsung Biologics has been strengthening its full-cycle CRDMO services. In 2025, it introduced organoid-based CRO services, and in 2026, it internalized master cell bank and vector production, thereby expanding its CDO capabilities.

Jung Hyungnam, Head of Bio Research Institute (Vice President) at Samsung Biologics, stated, "By providing CRO and CDO services from the early development stages of innovative new drugs, we aim to become a trusted new drug development partner for our clients. We will continue to develop innovative technologies and services to provide customized solutions for our customers."

This content was produced with the assistance of AI translation services.